EYLEA HD Label Update Enables Extended Dosing Intervals

Key Takeaways:

• The press release reports that the FDA updated the EYLEA HD label to permit consideration of individualized dosing intervals up to ~20 weeks in selected patients after sustained response in wAMD and DME.
• The announcement cites 96-week data from PULSAR (wAMD) and PHOTON (DME), reporting interval attainment among patients who completed the 96-week timepoint.
• The updated dosing language describes an initial monthly phase, 8–16-week maintenance dosing, potential extension to ~20 weeks after sustained response, and a return to more frequent dosing if response is not maintained.

The EYLEA HD (aflibercept) label update announcement reports that the FDA updated U.S. prescribing information to permit consideration of individualized dosing intervals up to approximately every 20 weeks in selected patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of sustained response. In the description, “successful response” is characterized in general terms as being based on visual and anatomic outcomes, without rigidly defined criteria, and the press release frames eligible patients as those who have maintained these improvements over time. The announcement also states that the label change incorporates longer-term trial data and expands the labeled range of injection intervals. This summary reflects the evidentiary basis cited and the dosing language described in the release.

The press release attributes the update to 96-week data from the pivotal PULSAR (wAMD) and PHOTON (DME) trials and describes sustained efficacy and safety through two years with extended dosing intervals. Among EYLEA HD–treated patients who completed week 96, the announcement reports that 71% and 47% of wAMD patients achieved last assigned dosing intervals of ≥16 weeks and ≥20 weeks, respectively, and 72% and 44% of DME patients achieved intervals of ≥16 weeks and ≥20 weeks, respectively. These figures are presented specifically for patients who completed the 96-week timepoint, representing a subset of the trial population and potentially subject to selection bias. Within that context, the 96-week findings are presented as supporting evidence for the FDA’s allowance of longer individualized dosing intervals.

Updated dosing language described in the announcement outlines a sequence beginning with three initial monthly doses, followed by maintenance dosing once every 8 to 16 weeks (±1 week). After one year of sustained response, the prescribing information language described in the release indicates that extension to approximately every 20 weeks (±1 week) may be considered in selected patients. The press release also notes that some patients may not maintain response on extended intervals and, for those individuals, describes a return to more frequent dosing (approximately every 4 weeks). Overall, the dosing approach is characterized as individualized within labeled ranges and contingent on maintaining treatment response.

With the label permitting 8–16-week maintenance dosing and the option to extend to approximately 20 weeks in appropriately selected patients, the announcement describes an expanded range of potential injection intervals for wAMD and DME.

On safety, the release lists common adverse reactions reported across approved indications (≥3%), including cataract, conjunctival hemorrhage, corneal epithelium defect, increased intraocular pressure, ocular discomfort (eye pain/irritation), retinal hemorrhage, blurred vision, vitreous detachment, and vitreous floaters. These adverse events are generally consistent with the known safety profile of intravitreal anti-VEGF therapies and are not specific to extended dosing intervals alone.

Overall, the announcement centers on FDA-permitted interval flexibility, framed around sustained visual and anatomic response and supported by longer-term pivotal trial data.